DBV Technologies Submits VIASKIN Peanut BLA and Reports Q3 2026 Financial Results
DBV Technologies (DBVT) has officially submitted a Biologics License Application (BLA) for its VIASKIN Peanut Patch, targeting children aged 4 to 7 years. The company is requesting Priority Review from the FDA and expects a determination on filing completeness by Q4 2026. As part of its transition toward becoming a commercial entity, DBVT has significantly increased spending on research, development, and sales infrastructure. Financially, the company reported a net loss of $64.5 million for the third quarter of 2026, compared to $33.2 million in the prior year. While a recent $50 million ADS sale helped bolster cash reserves to $165.7 million—providing a runway into Q3 2027—management noted substantial doubt regarding its ability to continue as a going concern beyond that period without additional capital.
Topics: biotechnology BLA submission cash runway clinical trials earnings report